mediola: olaparib and durvalumab for germline brca-mutated metastatic breast cancer
Published 4 years ago • 210 plays • Length 3:02Download video MP4
Download video MP3
Similar videos
-
2:57
olaparib and durvalumab in metastatic brca wild type triple-negative breast cancer
-
5:31
fda d.i.s.c.o.: olaparib for gbrcam her2-negative metastatic breast cancer
-
1:50
dr. domchek on results of the mediola trial in brca-mutated metastatic breast cancer
-
3:50
olaparib beneficial for brca-mutated her2-negative breast cancer
-
1:22
dora: durvalumab and olaparib in platinum treated advanced tnbc
-
5:18
recently approved drugs: olaparib for germline brca-mutated metastatic breast cancer
-
2:19
phase iii results of olaparib for brca breast cancer
-
4:24
the latest treatment options for brca-mutated breast cancer
-
6:04
germline brca mutations in tnbc
-
4:41
post neoadjuvant management in brca mutant breast cancer patients
-
9:17
i-spy 2: durvalumab in combination with olaparib and paclitaxel in high-risk her2 negative stage...
-
5:43
using olaparib in gbrca1/2 breast cancer
-
3:26
different treatment strategies for brca positive breast cancer
-
5:00
olympia: adjuvant olaparib delays recurrence of brca-mutant breast cancer | judy garber
-
3:04
advances in parp inhibitor use for metastatic breast cancer
-
1:00
#olaparib extends the life of #breastcancer patients harbouring particular #brca mutations #cancer
-
3:32
dora: using olaparib alone or with durvalumab in platinum responsive advanced triple-negative br...
-
8:09
olaparib improves disease-free survival in high-risk early-stage her2-negative breast cancer wit...
-
2:59
parp inhibitors for metastatic breast cancer